Stock·NYSE·Financial Services
Chubb Ltd (CB)
- Market cap
- $137.44B
- P/E
- 12.45
- Dividend yield
- 1.12%
- Street target
- $369.00median of 25 analysts
- 52-week range
- $273.35 $365.91
CB stock forecast today
Where CB stands today, and what CleaRank Financial AI makes of it.
CB at a glance
Chubb Ltd (CB): Buy, 77/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($342.27 and $333.15).
- Earnings CB beat estimates in 8 of its last 8 quarters, yet fell the next day after 5 of those beats.
- Insiders Insiders sold $89.6M and bought $3.0M over the last 18 months.
- Valuation P/E of 12.4 against 16.5 for the Financial Services sector: a discount to peers (-25%).
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates Chubb Ltd (CB) Buy, with a model score of 77/100.
The trend lifts the score most: the price is 6.94% above its 200-day average and 4.09% above its 50-day average, and the 50-day average is 2.74% above the 200-day. The 50-day average stands at $342.27 and the 200-day at $333.15. Over the past year the price rose 26.47%.
Only on CleaRank
Figures we compute ourselves from CB's own price, earnings and insider-filing history. Tap one to see it in context.
CB stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $356.25 is 4.1% above the 50-day simple moving average of $342.27.Price above its 200-day average ›
The price is 6.9% above the 200-day simple moving average of $333.15.50-day average above the 200-day ›
The 50-day average ($342.27) is 2.7% above the 200-day average ($333.15), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 90% of its 52-week range, between $273.35 and $365.91.
CB share price
Pick a period: each tab shows how far CB has moved over it, to the last close.
Today's trading
Where CB sits inside today's range and its 52-week range.
CB fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 12.45 is 24.6% below the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 2.21 is 41.8% below the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $11.2B on revenue of $62.0B, a net margin of 18.1%.Beat estimates in most recent reports ›
CB beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.12%, or $3.98 a share a year.
Key statistics
The headline figures for CB.
As of October 27, 2026, CB trades at $356.25, with a market value of $137.44B, a P/E ratio of 12.45 and a dividend yield of 1.12%.
What the numbers say
CleaRank Financial AI's reading of CB's valuation, growth and risks.
CB's trailing P/E of 12.45 is 24.6% below the Financial Services median of 16.5, and the peer comparison on this page rates that as a discount to peers. Measured on sales, the P/S of 2.21 is 41.8% below the sector median of 3.8. For scale, the company's market value stands at $137.4B.
On profitability, the net margin comes in at 18.12% and the operating margin at 21.37%. Return on equity is 14.25%, above the sector median of 13.8%. The balance sheet shows debt-to-equity of 0.27, and the trailing dividend yield is 1.12%, or $3.98 a share a year.
CB beat expectations in the October 20, 2026 report by 12.65%, with EPS of $7.66 against the $6.80 that analysts had forecast. Even so, the stock fell 0.78% in the next session.
Across its last 8 reports, CB beat the estimate every time, but beats have not guaranteed gains: the stock fell the next day after 5 of them. Earlier, the stock rose 5.13% after the February 3, 2026 report, a beat of 10.91%. Analysts' average EPS estimate for this fiscal year is $28.89, which would be growth of 16.5%, and $29.38 for next year (growth of 1.7%).
Plan around day-to-day swings first. On an average session CB has moved 1.17%, and its beta against the S&P 500 is 0.37.
CB against the Financial Services sector
How CB compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: CB trades at a notable discount to sector peers (-25%), which may indicate undervaluation or specific company headwinds.
Return vs XLF: Since May 15, 2025, CB has gained 22.0% against a gain of 9.0% for XLF.
Performance against XLF
CB and the Financial Services sector fund over the same days.
Revenue and earnings
How much CB sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); CB reported again on October 20, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 6.5% in FY2025 to $59.8B, from $56.2B a year earlier.
Profit margin: The net margin was 17.8% in FY2025, up from 17.2% the year before.
Profitable: CB earned $10.6B in FY2025.
Earnings reality check
Did CB beat what analysts expected, and how did the stock react?
Earnings record: CB beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 5 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 20, 2026after close | $6.80 | $7.66 | +12.65% | -0.78% | -0.42% |
| Jul 21, 2026after close | $6.75 | $7.26 | +7.56% | -3.26% | +2.45% |
| Apr 21, 2026after close | $6.61 | $6.82 | +3.18% | -1.17% | +0.32% |
| Feb 3, 2026after close | $6.78 | $7.52 | +10.91% | +5.13% | +4.11% |
| Oct 21, 2025after close | $6.16 | $7.49 | +21.59% | +2.70% | +2.35% |
| Jul 22, 2025after close | $5.97 | $6.14 | +2.85% | -3.08% | -3.65% |
| Apr 22, 2025after close | $3.23 | $3.68 | +13.93% | -2.04% | -1.88% |
| Jan 28, 2025after close | $5.45 | $6.02 | +10.46% | +1.31% | -0.01% |
As of October 27, 2026, CB has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on October 20, 2026, came in 12.65% above the estimate and the stock moved -0.78% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CB AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 59.5, in neutral territory.RSI above 50 ›
An RSI of 59.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of CB
The score, the reasoning behind it, and what could move the price next.
Chubb Ltd (CB) is in an upward trend. The price of $356.25 sits 4.09% above its 50-day average of $342.27 and 6.94% above its 200-day average of $333.15. The stock trades at 90% of its 52-week range, so the price is 2.64% below the 52-week high of $365.91. Meanwhile the 50-day average is 2.74% above the 200-day average.
The short and long run point different ways: the price rose 6.86% over the past month, fell 1.99% over the past three months and rose 26.47% over the past year. On momentum, the 14-day RSI reads 59.5, in the neutral zone, with the MACD line positive.
Earnings beat, but the stock fell ›
The October 20, 2026 report beat the EPS estimate by 12.65%, and the share price fell 0.78% in the first session after it.
Source: Earnings report, October 20, 2026Rating reaffirmed ›
JP Morgan kept its Neutral rating on October 23, 2026.
Source: Analyst action, JP Morgan, October 23, 2026
- Keep an eye on the two closest levels: the 52-week high of $365.91 above the price, and the 20-day EMA at $349.82 below it.
- The 14-day RSI is 59.5, which is neutral, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- The share price fell 0.78% in the first session after the October 20, 2026 report. CB has nonetheless beaten estimates in 8 of the last 8 reports.
CB trades above its 50-day and 200-day moving averages ($342.27 and $333.15), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 20-day EMA at $349.82.
The next level overhead for CB is the 52-week high of $365.91.
Technical indicators
Momentum and trend for CB, from its daily closes.
As of October 27, 2026, with CB at $356.25, its 14-day RSI is 59.5 (neutral territory), its 50-day simple moving average is $342.27 and its 200-day is $333.15.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CB moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, CB's 1-year correlation of daily returns is +0.08 with S&P 500 (SPY), -0.11 with Nasdaq 100 (QQQ), -0.16 with Bitcoin (BTC) and -0.09 with gold (XAU).
CB price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
9 of 25 analysts rate it a buy or strong buy, 13 a hold and 3 a sell.Median target above the price ›
The median 12-month target of $369.00 is 3.6% above the price.More buy ratings than three months ago ›
9 of 25 rate it a buy now, against 9 of 25 three months ago.
CB Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 23, 2026 | JP Morgan | Maintains | Neutral |
| Oct 22, 2026 | Citigroup | Maintains | Buy |
| Oct 22, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Oct 22, 2026 | Mizuho | Maintains | Neutral |
| Oct 21, 2026 | Cantor Fitzgerald | Reiterates | Neutral |
| Oct 12, 2026 | Wells Fargo | Maintains | Equal-Weight |
As of October 27, 2026, 25 Wall Street analysts cover CB: 9 rate it a buy or strong buy, 13 a hold and 3 a sell or strong sell. Their 12-month price targets range from $314.00 to $425.00. The median CB price target is $369.00, 3.6% above the price of $356.25.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CB trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CB trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CB's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CB tends to move, against the market and on its own.
CB price history and drawdowns
CB's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.17% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 39.4%, from February 2020 to May 2020, regained by February 2021.Most 1-year holds ended higher ›
77% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $33,155, against $42,376 in the S&P 500 (SPY).
CB Drawdowns & Recovery
As of October 27, 2026, CB's worst peak-to-trough fall over the last 10 years with dividends reinvested was -39.4% (February 2020 to May 2020); it regained that peak by February 2021, 9 months after the low, and 77% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CB in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CB trailed the S&P 500 over this period: $33,155 against $42,376.
A $10,000 investment in CB in October 2016 would be worth about $33,155 today with dividends reinvested, compared with about $42,376 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CB, and which have not.
Strongest month, November: an average of +3.70%, up in 5 of 10 years.
Weakest month, March: an average of -3.26%, up in 4 of 10 years.
This month, October: has averaged +3.38%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CB's strongest calendar month has been November (average +3.70%, up in 5 of 10 years) and its weakest March (average -3.26%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
CB stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CB, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in CB today could grow to about $13,621 by 2030 in the base case, with a 90th-percentile outcome near $25,198 and a 10th-percentile outcome around $7,363. The simulation models price only; at today's 1.12% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CB Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $485 for CB by 2030 in the base case, from $356 today (1.4x over 4 years). The 10th-percentile path ends near $262. These are outcomes of a Monte Carlo simulation run on CB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $283 | $385 | $523 | |
| 2028 | $269 | $416 | $642 | |
| 2029 | $264 | $449 | $765 | |
| 2030 | $262 | $485 | $898 |
Method: a lognormal simulation of CB's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
CB insider trading
What the people running the company have bought and sold.
CB insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $3.0M on the open market and sold $89.6M.
As of October 27, 2026, CB insiders reported 25 open-market sales worth $89.6M and 2 open-market purchases worth $3.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 21, 2026 | Michael P Connors
Director
|
Sell | 5.5K | $1.9M |
| Jul 28, 2026 | Joseph F Wayland
General Counsel
|
Sell | 8.5K | $3.1M |
| Jun 8, 2026 | Juan Luis Ortega
Officer
|
Sell | 3.9K | $1.3M |
| Jun 8, 2026 | Juan Luis Ortega
Officer
|
Option | 3.9K | $540.2K |
| May 28, 2026 | John W Keogh
President
|
Grant | 62.4K | - |
| May 27, 2026 | John W Keogh
President
|
Sell | 23.0K | $7.4M |
| May 21, 2026 | Michael G Atieh
Director
|
Sell | 578 | $190.5K |
| May 21, 2026 | Michael G Atieh
Director
|
Grant | 681 | - |
| May 21, 2026 | Nancy Buese
Director
|
Grant | 1.1K | - |
| May 21, 2026 | Nelson J Chai
Director
|
Grant | 681 | - |
| May 21, 2026 | Michael P Connors
Director
|
Grant | 681 | - |
| May 21, 2026 | Michael L Corbat
Director
|
Grant | 681 | - |
| May 21, 2026 | Fred Zuliu Hu
Director
|
Grant | 1.1K | - |
| May 21, 2026 | Robert J Hugin
Director
|
Grant | 1.1K | - |
| May 21, 2026 | Robert W Scully
Director
|
Grant | 1.3K | - |
| May 21, 2026 | Theodore E Shasta
Director
|
Grant | 681 | - |
| May 21, 2026 | David H Sidwell
Director
|
Grant | 757 | - |
| May 21, 2026 | Olivier Steimer
Director
|
Grant | 681 | - |
| May 21, 2026 | Frances Fragos Townsend, J.D.
Director
|
Grant | 681 | - |
| Mar 19, 2026 | Olivier Steimer
Director
|
Sell | 2.0K | $658.6K |
| Mar 6, 2026 | George F Ohsiek
Officer
|
Sell | 770 | $250.4K |
| Mar 4, 2026 | Bryce L Johns
Officer
|
Sell | 1.5K | $504.9K |
| Mar 3, 2026 | Joseph F Wayland
General Counsel
|
Sell | 7.6K | $2.6M |
| Mar 2, 2026 | Peter C Enns
Chief Financial Officer
|
Grant | 5.4K | - |
| Mar 2, 2026 | Evan G Greenberg
Chief Executive Officer
|
Grant | 49.9K | - |
| Mar 2, 2026 | Bryce L Johns
Officer
|
Grant | 4.3K | - |
| Mar 2, 2026 | John W Keogh
President
|
Grant | 14.4K | - |
| Mar 2, 2026 | Paul Mcnamee
Officer
|
Grant | 1.2K | - |
| Mar 2, 2026 | Frances D O'Brien
Officer
|
Grant | 1.1K | - |
| Mar 2, 2026 | George F Ohsiek
Officer
|
Grant | 1.2K | - |
| Mar 2, 2026 | Juan Luis Ortega
Officer
|
Grant | 904 | - |
| Mar 2, 2026 | Joseph F Wayland
General Counsel
|
Grant | 3.5K | - |
| Feb 13, 2026 | George F Ohsiek
Officer
|
Sell | 5.1K | $1.7M |
| Feb 12, 2026 | Evan G Greenberg
Chief Executive Officer
|
Sell | 14.9K | $5.0M |
| Feb 12, 2026 | George F Ohsiek
Officer
|
Option | 2.1K | $250.0K |
| Feb 6, 2026 | Timothy Alan Boroughs
Chief Investment Officer
|
Sell | 27.8K | $9.2M |
| Feb 6, 2026 | Timothy Alan Boroughs
Chief Investment Officer
|
Option | 27.8K | $3.8M |
| Feb 5, 2026 | Evan G Greenberg
Chief Executive Officer
|
Sell | 15.1K | $5.0M |
| Dec 15, 2025 | Evan G Greenberg
Chief Executive Officer
|
Option | 844 | $99.9K |
| Dec 2, 2025 | Juan Luis Ortega
Officer
|
Sell | 4.4K | $1.3M |
| Dec 2, 2025 | Juan Luis Ortega
Officer
|
Sell | 864 | $253.7K |
| Nov 24, 2025 | Timothy Alan Boroughs
Chief Investment Officer
|
Sell | 11.4K | $3.4M |
| Nov 24, 2025 | Timothy Alan Boroughs
Chief Investment Officer
|
Grant | 850 | - |
| Nov 18, 2025 | Evan G Greenberg
Chief Executive Officer
|
Grant | 3.3K | - |
| Nov 14, 2025 | John J Lupica
Officer
|
Sell | 16.4K | $4.9M |
| Nov 13, 2025 | Joseph F Wayland
General Counsel
|
Sell | 5.8K | $1.7M |
| Oct 27, 2025 | John J Lupica
Officer
|
Sell | 23.7K | $6.7M |
| Oct 27, 2025 | John J Lupica
Officer
|
Option | 23.7K | $2.8M |
| Jul 25, 2025 | Michael L Corbat
Director
|
Buy | 425 | $114.7K |
| Jul 1, 2025 | John J Lupica
Officer
|
Sell | 5.5K | $1.6M |
| Jul 1, 2025 | John J Lupica
Officer
|
Option | 2.9K | $344.2K |
| Jun 20, 2025 | John W Keogh
President
|
Grant | 1.1K | - |
| Jun 16, 2025 | Michael G Atieh
Director
|
Sell | 538 | $154.7K |
| Jun 6, 2025 | John W Keogh
President
|
Sell | 9.8K | $2.9M |
| Jun 6, 2025 | John W Keogh
President
|
Buy | 9.8K | $2.9M |
| Jun 4, 2025 | Joseph F Wayland
General Counsel
|
Sell | 5.3K | $1.5M |
| May 21, 2025 | John W Keogh
President
|
Sell | 85.1K | $24.7M |
| May 21, 2025 | John W Keogh
President
|
Option | 65.9K | $8.4M |
| May 20, 2025 | Juan Luis Ortega
Officer
|
Sell | 6.5K | $1.9M |
| May 20, 2025 | Juan Luis Ortega
Officer
|
Option | 6.5K | $770.0K |
| May 15, 2025 | Michael G Atieh
Director
|
Grant | 771 | - |
| May 15, 2025 | Nancy K. Buese
Director
|
Grant | 1.3K | - |
| May 15, 2025 | Sheila P Burke
Director
|
Grant | 771 | - |
| May 15, 2025 | Nelson J Chai
Director
|
Grant | 771 | - |
| May 15, 2025 | Michael P Connors
Director
|
Grant | 771 | - |
| May 15, 2025 | Michael L Corbat
Director
|
Grant | 771 | - |
| May 15, 2025 | Fred Zuliu Hu
Director
|
Grant | 771 | - |
| May 15, 2025 | Robert J Hugin
Director
|
Grant | 1.3K | - |
| May 15, 2025 | Robert W Scully
Director
|
Grant | 1.4K | - |
| May 15, 2025 | Theodore E Shasta
Director
|
Grant | 771 | - |
| May 15, 2025 | David H Sidwell
Director
|
Grant | 771 | - |
| May 15, 2025 | Olivier Steimer
Director
|
Grant | 771 | - |
| May 15, 2025 | Frances Fragos Townsend, J.D.
Director
|
Grant | 771 | - |
Source: TwelveData, from reported insider filings
CB stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.